Comparative Pharmacology
Head-to-head clinical analysis: DHIVY versus KIMIDESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DHIVY versus KIMIDESS.
DHIVY vs KIMIDESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
DHIVY is not a recognized drug. No dosing information available.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when CrCl <30 mL/min).
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive